Dosing & Uses
Dosage Forms & Strengths
capsule
- 75mg
- 150mg
- 300mg
injectable solution
- 150mg/mL
oral solution
- 75mg/5mL
intravenous ready-to-use solution
- 300 mg/50mL (5% dextrose)
- 600 mg/50mL (5% dextrose)
- 900 mg/50mL (5% dextrose)
Serious Infections Caused by Anaerobic Bacteria
150-450 mg PO q6-8hr; not to exceed 1.8 g/day, OR
1.2-2.7 g/day IV/IM divided q6-12hr; not to exceed 4.8 g/day
Amnionitis
450-900 mg IV q8hr
Inhalational & Gastrointestinal Anthrax (Off-label)
900 mg IV q8hr with ciprofloxacin 400 mg PO q12hr or doxycycline 150-300 mg PO q12hr
Bacterial Vaginosis
300 mg PO q12hr for 7 days
Surgical Prophylaxis
900 mg PO/IV 1 hr prior to procedure; may redose q6hr if necessary
Bite Wounds (Human or Animal)
300 mg PO q6hr
Gangrenous Pyomyositis
900 mg IV q8hr with penicillin G
Group B Streptococcus
Neonatal prophylaxis
900 mg IV q8hr until delivery
Orofacial/Parapharyngeal Space Infections
150-450 mg PO q6hr for at least 7 days; not to exceed 1.8 g/day, OR
600-900 mg IV q8hr
Pelvic Inflammatory Disease
900 mg IV q8hr with gentamicin 2 mg/kg; THEN 1.5 mg/kg q8hr; continue after discharge with doxycycline 100 mg PO q12hr to complete 14 days of therapy
Toxic Shock Syndrome
900 mg IV q8hr plus oxacillin or nafcillin (2 g IV q4hr) or vancomycin (30 mg/kg/day IV divided q12hr
Endocarditis Prophylaxis (Off-label)
600 mg PO/IV/IM 30-60 min before procedure
Avoid IM injections in patients receiving anticoagulant therapy; administer PO in these circumstances; in general, administer IV only if patient does not tolerate or is unable to absorp oral medications
Dosing considerations
- Recent AHA guidelines recommend only for high-risk patients undergoing invasive procedures
CNS Toxoplasmosis, With Pyrimethamine or Leucovorin (Off-label)
600 mg IV or PO q6hr for at least 6 weeks
Gardnerella Vaginalis (Off-label)
PO: 300 mg PO q12hr for 7 days
Pneumocystis (Carinii) Jiroveci (Off-label)
300-450 mg PO q6-8hr with primaquine for 21 days
600-900 mg IV q6-8hr with primaquine for 21 days
Sarcoidosis (Orphan)
Orphan indication sponsor
- Autoimmunity Research Foundation; 3423 Hill Canyon Avenue; Thousand Oaks, CA 91360
Administration
PO: May take with food
Dosage Forms & Strengths
capsule
- 75mg
- 150mg
- 300mg
injectable solution
- 150mg/mL
oral solution
- 75mg/5mL
intravenous ready-to-use solution
- 300 mg/50mL (5% dextrose)
- 600 mg/50mL (5% dextrose)
- 900 mg/50mL (5% dextrose)
Serious Infections Caused by Anaerobic Bacteria
<7 days
- <2 kg (or >7 days, <1.2 kg): 10 mg/kg/day IV/IM divided q12hr
- >2 kg (or >7 days, 1.2-2 kg): 15 mg/kg/day IV/IM divided q8hr
>7 days
- >2 kg: 20 mg/kg/day IV/IM divided q6hr
<1 month
- 15-20 mg/kg/day divided q6-8hr
>1 month
- Hydrochloride: 8-20 mg/kg/day PO
- Palmitate: 8-25 mg/kg/day divided q6-8hr; 37.5 mg q8hr minimum palmitate dose
Anthrax
15-40 mg/kg/day IV divided q6-8hr
8-25 mg/kg/day PO divided 6-8hr
Endocarditis
Prophylaxis
20 mg/kg PO 30-60 min before procedure, OR
20 mg/kg IV/IM within 30-60 minutes before procedure
Streptococcal Pharyngitis
May consider use in patients allergic to penicillin (IDSA guidelines)
Chronic carrier treatment: 20-30 mg/kg/day PO divided q8hr; not to exceed 300 mg/dose
Acute treatment in penicillin-allergic patients: 7 mg/kg/dose TID for 10 days; not to exceed 300 mg/dose
Orofacial Infections
10-20 mg/kg/day PO divided q6-8hr, OR
15-25 mg/kg/day IV divided q6-8hr
May adjust dose as necessary not to exceed 40 mg/kg/day
Dosing Considerations
IM: No more than 600 mg per injection
Endocarditis: Recent AHA guidelines recommend only for invasive procedures in high-risk patients
Administration
May take with food
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (12)
- atracurium
clindamycin increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- BCG vaccine live
clindamycin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- cholera vaccine
clindamycin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
- cisatracurium
clindamycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- onabotulinumtoxinA
clindamycin increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- pancuronium
clindamycin increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- rapacuronium
clindamycin increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- rimabotulinumtoxinB
clindamycin increases effects of rimabotulinumtoxinB by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- rocuronium
clindamycin increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- succinylcholine
clindamycin increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- typhoid vaccine live
clindamycin decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- vecuronium
clindamycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
Monitor Closely (17)
- bazedoxifene/conjugated estrogens
clindamycin will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- conjugated estrogens
clindamycin will decrease the level or effect of conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- dienogest/estradiol valerate
clindamycin will decrease the level or effect of dienogest/estradiol valerate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. An alternate or additional form of birth control may be advisable during concomitant use.
- digoxin
clindamycin will increase the level or effect of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.
- estradiol
clindamycin will decrease the level or effect of estradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estrogens conjugated synthetic
clindamycin will decrease the level or effect of estrogens conjugated synthetic by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estropipate
clindamycin will decrease the level or effect of estropipate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- ethinylestradiol
clindamycin will decrease the level or effect of ethinylestradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- incobotulinumtoxinA
clindamycin increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- letermovir
letermovir increases levels of clindamycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
clindamycin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy.
- mestranol
clindamycin will decrease the level or effect of mestranol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- mipomersen
mipomersen, clindamycin. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.
- nitazoxanide
nitazoxanide, clindamycin. Either increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor.
- ospemifene
clindamycin, ospemifene. Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.
- sodium picosulfate/magnesium oxide/anhydrous citric acid
clindamycin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.
- warfarin
clindamycin increases effects of warfarin by Other (see comment). Use Caution/Monitor. Comment: Decr vitamin K-producing intestinal flora may increase INR after a few days.
Minor (11)
- balsalazide
clindamycin will decrease the level or effect of balsalazide by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- biotin
clindamycin will decrease the level or effect of biotin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- erythromycin base
clindamycin, erythromycin base. Either decreases effects of the other by pharmacodynamic antagonism. Minor/Significance Unknown.
- erythromycin ethylsuccinate
clindamycin, erythromycin ethylsuccinate. Either decreases effects of the other by pharmacodynamic antagonism. Minor/Significance Unknown.
- erythromycin lactobionate
clindamycin, erythromycin lactobionate. Either decreases effects of the other by pharmacodynamic antagonism. Minor/Significance Unknown.
- erythromycin stearate
clindamycin, erythromycin stearate. Either decreases effects of the other by pharmacodynamic antagonism. Minor/Significance Unknown.
- food
food decreases levels of clindamycin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- pantothenic acid
clindamycin will decrease the level or effect of pantothenic acid by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pyridoxine
clindamycin will decrease the level or effect of pyridoxine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pyridoxine (Antidote)
clindamycin will decrease the level or effect of pyridoxine (Antidote) by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- thiamine
clindamycin will decrease the level or effect of thiamine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Abdominal pain
Agranulocytosis
Eosinophilia (transient)
Diarrhea
Fungal overgrowth
Pseudomembranous colitis
Hypersensitivity
Stevens-Johnson syndrome
Rashes
Urticaria
Hypotension
Nausea
Vomiting
Sterile abscess at IM site
Thrombophlebitis
Granulocytopenia
Neutropenia
Thrombocytopenia
Polyarthritis
Renal dysfunction
Postmarketing reports
Metallic taste
Clostridium difficile colitis
Warnings
Black Box Warnings
Clostridium difficile-associated diarrhea (CDAD) has been reported and may range in severity from mild diarrhea to fatal colitis
C difficile produces toxins A and B, which contribute to CDAD; hypertoxin-producing C difficile strains increase morbidity and mortality (more likely to be refractory to antimicrobial therapy and may require colectomy)
If CDAD suspected or confirmed, ongoing antibiotic use not directed against C difficile may need to be discontinued
Contraindications
Hypersensitivity to clindamycin, lincomycin, or formulation components
Cautions
Endocarditis prophylaxis: Use only for high-risk patients, per recent AHA guidelines
Risk of potentially fatal pseudomembranous colitis, fungal or bacterial superinfection on prolonged use; discontinue therapy if significant abdominal cramps, diarrhea, or passage of blood and mucus occurs
May increase risk of drug-resistant bacteria if prescribed in the absence of proven or strongly suspected bacterial infection
Use caution in hepatic impairment, monitor for hepatic abnormalities; periodic liver enzyme determinations should be made when treating patients with severe liver disease
Not for use in meningitis due to inadequate penetration into CSF
Severe skin reactions including toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS), some with fatal outcome, reported; permanently discontinue if reactions occur
Parenteral product contains benzyl alcohol, which has been associated with gasping syndrome and death in newborns
Use with caution in patients with history of gastrointestinal disease, especially colitis
Not for administration as a bolus; infuse over 10-60 min
Consider possibility of clostridium difficile in all patients who present with diarrhea following antibiotic use
Serious anaphylactic reactions require immediate emergency treatment with epinephrine; oxygen and intravenous corticosteroids should also be administered as indicated
Prescribe with caution in atopic individuals
Indicated surgical procedures should be performed in conjunction with antibiotic therapy
Clindamycin dosage modification may not be necessary in patients with renal disease
Discontinue therapy permanently and institute appropriate therapy if anaphylactic or severe hypersensitivity reaction occurs
Pregnancy & Lactation
Pregnancy
In clinical trials with pregnant women, systemic administration of clindamycin during the second and third trimesters, has not been associated with increased frequency of congenital abnormalities
Clindamycin should be used during first trimester of pregnancy only if clearly needed; there are no adequate and well-controlled studies in pregnant women during first trimester of pregnancy. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed
Lactation
Clindamycin has been reported to appear in breast milk in range of 0.5 to 3.8 mcg/mL; clindamycin has potential to cause adverse effects on breastfed infant's gastrointestinal flora; if oral or intravenous clindamycin is required by nursing mother, it is not a reason to discontinue breastfeeding, but alternate drug may be preferred; monitor infant for possible adverse effects on gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in stool indicating possible antibiotic-associated colitis
The developmental and health benefits of breastfeeding should be considered along with mother's clinical need for clindamycin and any potential adverse effects on breastfed child from clindamycin or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Suppresses protein synthesis by binding to 50S ribosomal subunits; bacteriostatic or bactericidal depending on drug concentration, organism and infection site
Absorption
Bioavailability: Oral (rapid; 90%)
Peak serum time: Within 60 min (PO); 1-3 hr (IM)
Distribution
High concentrations in bone and urine
No significant levels in CSF, even with inflamed meninges
Crosses placenta; enters breast milk
Vd: ~2 L/kg
Metabolism
Hepatic
Elimination
Half-life: 2-3 hr (adults); 8.7 hr (premature neonates); 3.6 hr (full-term neonates); 2 hr (children); 4 hr (elderly)
Excretion: Urine (10%) as active drug; feces (~4%) as active drug
Administration
IV Incompatibilities
Additive: Aminophylline, ceftriaxone, ciprofloxacin, gentamicin/cefazolin, ranitidine(?)
Syringe: Tobramycin
Y-site: Allopurinol, azithromycin, doxapram, filgrastim, fluconazole, idarubicin
Reported to be physically incompatible with aminophylline, ampicillin, barbiturates, Ca-gluconate, magnesium sulfate, and phenytoin; other reports say ampicillin is additive compatible and magnesium sulfate is Y-site compatible
IV Compatibilities
Solution: Compatible with most common diluents
Additive: Amikacin, aztreonam, cefazolin, cefepime, cefoperazone, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cimetidine, fluconazole, gentamicin, heparin, hydrocortisone, kanamycin, methylprednisolone, metoclopramide, metronidazole, netilmicin, ofloxacin, KCl, penicillin G, piperacillin, Na-bicarbonate, tobramycin, verapamil, vitamin B/C
Syringe: Amikacin, aztreonam, caffeine, gentamicin, heparin
Y-site: Amifostine, amiodarone, amphotericin B CholSO4, amsacrine, aztreonam, bivalirudin, cefpirome, cisatracurium, cyclophosphamide, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposomal, enalaprilat, esmolol, etoposide PO4, fenoldopam, fludarabine, foscarnet, gatifloxacin, gemcitabine, granisetron, hetastarch, hydromorphone, heparin, labetalol, levofloxacin, linezolid, meperidine, morphine, midazolam, milrinone, nicardipine, ondansetron, perphenazine, piperacillin/tazobactam, propofol, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa, vinorelbine, vitamin B/C, zidovudine
IV Preparation
150 mg/mL solution for injection must be diluted before infused IV
Dilute 300 and 600 mg in 50 mL of D5W
Dilute 900 mg in 50-100 mL of D5W
Dilute 1200 mg in 100 mL of D5W
IV Administration
Intermittent IV infusion
- Infuse over 10-60 min at a rate not exceeding 30 mg/min
- See manufacturer's PI for rapid and maintenance rates for specific desired serum levels
- 300 mg doses infuse over 10 min
- 600 mg doses infuse over 20 min
- 900 mg doses infuse over 30 min
- 1200 mg doses infuse over 60 min; no more than 1200 mg of drug should be given by IV infusion in 1 hr
Continuous IV infusion
- May give continuous IV infusion instead of intermittent after first dose has been given by rapid IV infusion
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Cleocin vaginal - | 100 mg suppos |  | |
| Cleocin vaginal - | 2 % cream |  | |
| Clindacin ETZ topical - | 1 % swab |  | |
| Clindacin ETZ topical - | 1 % kit |  | |
| Clindacin ETZ topical - | 1 % swab |  | |
| Cleocin injection - | 150 mg/mL vial |  | |
| Cleocin injection - | 150 mg/mL vial |  | |
| Cleocin injection - | 150 mg/mL vial |  | |
| Cleocin injection - | 150 mg/mL vial |  | |
| Cleocin injection - | 150 mg/mL vial |  | |
| clindamycin phosphate topical - | 1 % gel |  | |
| clindamycin phosphate topical - | 1 % gel |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % gel |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % foam |  | |
| clindamycin phosphate topical - | 1 % foam |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % swab |  | |
| clindamycin phosphate topical - | 1 % lotion |  | |
| clindamycin phosphate topical - | 1 % gel |  | |
| clindamycin phosphate topical - | 1 % gel |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % lotion |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % solution |  | |
| clindamycin phosphate topical - | 1 % swab |  | |
| Clindacin P topical - | 1 % swab |  | |
| clindamycin vaginal - | 2 % cream |  | |
| clindamycin vaginal - | 2 % cream |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| clindamycin injection - | 150 mg/mL vial |  | |
| Clindagel topical - | 1 % gel |  | |
| Clindesse vaginal - | 2 % cream |  | |
| Evoclin topical - | 1 % foam |  | |
| Evoclin topical - | 1 % foam |  | |
| Cleocin T topical - | 1 % solution |  | |
| Cleocin T topical - | 1 % swab |  | |
| Cleocin T topical - | 1 % gel |  | |
| Cleocin T topical - | 1 % lotion |  | |
| Cleocin T topical - | 1 % gel |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
clindamycin vaginal
CLINDAMYCIN PHOSPHATE SINGLE DOSE CREAM - VAGINAL
(klin-da-MYE-sin)
COMMON BRAND NAME(S): Clindesse
USES: This medication is used to treat a certain type of vaginal infection (bacterial vaginosis) in women who are not pregnant. Clindamycin is an antibiotic that works by stopping the growth of bacteria.
HOW TO USE: Read the Patient Information Leaflet that comes with this product for instructions on the proper use of this medication. Consult your doctor or pharmacist if you have any questions.This product is for vaginal use only. Wash your hands before and after use. Avoid contact of this cream with your eyes. If it gets into your eyes, wash them right away with plenty of water. Call your doctor if eye irritation persists.Insert the applicator filled with medication high into the vagina and press the plunger to release the medication. This product is given as a single dose. This product may be used at any time of the day because it is designed to leak very little medication out of the vagina.Tell your doctor if your condition does not improve after several days.
SIDE EFFECTS: Although uncommon, mild stomach upset may occur. If this effect persists or worsens, tell your doctor or pharmacist promptly.Rarely, vaginal discomfort/burning/itching/discharge may occur or worsen. These symptoms may be due to a new vaginal infection (such as a yeast/fungal infection). Contact your doctor if you notice a change in vaginal discharge or other new vaginal symptoms.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.A very small amount of this medication may be absorbed into your blood and may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped. Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool.If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using clindamycin, tell your doctor or pharmacist if you are allergic to it; or to lincomycin; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: intestinal disease (such as C. difficile-associated diarrhea, enteritis, ulcerative colitis).Before using this medication, tell your doctor or pharmacist your medical history.Do not have vaginal intercourse or use tampons or douches during treatment with this medication because these can cause the cream to not work as well.The mineral oil in this product can weaken rubber products such as latex condoms and diaphragms and lead to their failure. Do not use these products during treatment with this medication and for 5 days after treatment is over. Consult your doctor about other forms of barrier protection/birth control (e.g., polyurethane condoms) during this time.During pregnancy, this medication should be used only when clearly needed. Antibiotics taken by mouth have been used to treat vaginal infections during pregnancy, especially high-risk pregnancies (e.g., if there is a risk of early childbirth). Consult your doctor for more details and to discuss the risks and benefits.It is unknown if the medication in this product passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
OVERDOSE: This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Do not share this medication with others.This medication has been prescribed for your current condition only. Do not use it later for another infection unless your doctor tells you to.
MISSED DOSE: Not applicable.
STORAGE: Store at room temperature away from heat and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
